The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for bumetanide nasal spray (RSQ-777) for the treatment of edema associated with congestive heart failure, ...
Nicotine inhalation system 10mg (4mg delivered ... Inhaler: peak plasma concentrations of 49ng/mL reached within 15 minutes. Nasal spray: maximum venous concentrations of 2–12ng/mL reached ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback